Posted by Michael Wonder on 27 Dec 2018
Acer Therapeutics announces FDA acceptance of NDA and priority review for Edsivo for the treatment of vEDS
26 December 2018 - Acer continues progress toward goal of commercialising Edsivo.
Acer Therapeutics today announced that the U.S. FDA has accepted for review Acer’s new drug application for Edsivo for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen mutation.
The FDA also granted a priority review of the application and assigned a Prescription Drug User Fee Act target action date of 25 June 2019.
